Waverly Advisors LLC Grows Position in Stryker Co. (NYSE:SYK)

Waverly Advisors LLC grew its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 148.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,933 shares of the medical technology company's stock after buying an additional 2,948 shares during the period. Waverly Advisors LLC's holdings in Stryker were worth $1,776,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. J. W. Coons Advisors LLC raised its stake in Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC increased its holdings in shares of Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after purchasing an additional 27 shares during the period. Opal Wealth Advisors LLC increased its holdings in shares of Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after purchasing an additional 28 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares during the period. Finally, JFS Wealth Advisors LLC boosted its stake in shares of Stryker by 4.4% in the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock valued at $247,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 0.3%

NYSE:SYK traded down $1.27 during trading hours on Monday, hitting $377.01. 1,579,798 shares of the company were exchanged, compared to its average volume of 1,348,410. The company has a fifty day simple moving average of $368.06 and a 200 day simple moving average of $376.14. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market capitalization of $143.90 billion, a price-to-earnings ratio of 48.58, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.50 earnings per share. Sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is presently 45.41%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the company. BTIG Research set a $403.00 price target on Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Needham & Company LLC restated a "buy" rating and issued a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Argus set a $450.00 target price on shares of Stryker in a research report on Monday, February 3rd. Citigroup reiterated a "buy" rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a research report on Thursday. Finally, The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, Stryker presently has an average rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.